Loading...
•
Dec 31, 2024
Standard Biotool Q4 2024 Earnings Report
Standard BioTools reported a decrease in revenue and net loss, alongside an improvement in adjusted EBITDA for the fourth quarter of 2024.
Key Takeaways
Standard BioTools announced its financial results for the fourth quarter and full fiscal year ended December 31, 2024. The company reported a total revenue of $46.7 million for Q4 2024, with a net loss of $34.1 million and an adjusted EBITDA loss of $18.4 million, showing improvements compared to the previous year.
Full year 2024 pro forma combined revenue reached $175.1 million.
The company achieved a 17% Full Year reduction in pro forma operating loss and a 33% year-over-year improvement in adjusted EBITDA.
An additional $10 million in operational cost reductions were realized, bringing the total synergies to $90 million over 12 months.
Standard BioTools maintains a strong balance sheet with $295 million in cash, cash equivalents, restricted cash, and short-term investments, with no material debt at year-end 2024.
Revenue by Segment
Forward Guidance
For fiscal year 2025, Standard BioTools expects revenue to be in the range of $165 million to $175 million.
Positive Outlook
- Continued focus on execution with precision and continuous improvement.
- Intelligent scaling both organically and inorganically.
- Shifting mix towards higher-margin offerings in attractive markets.
- Unlocking the power of proteomics with partner Illumina.
- Imminent launch of co-branded, NGS-based, distributed solution targeting a billion-dollar opportunity.
Challenges Ahead
- Anticipated high single-digit millions decline in Americas academic revenue due to NIH funding pressures.
- Uncertain economic environment.
- No expected effect from U.S. export controls (implies potential for future impact).
- Limited impact from tariffs (implies potential for future impact).
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...